FDA Approves New Pancreatic Cancer Drug

Aug 26, 2026

53 min

Aug 26, 2026 19:31

FDA approves groundbreaking pancreatic cancer drug

## FDA Approval of Daraxonrasib

The U.S. Food and Drug Administration (FDA) has approved a new drug, daraxonrasib, for advanced pancreatic cancer. This marks a significant development in treating a cancer type known for its high mortality rate. The drug targets a mutation present in over 90% of pancreatic cancer cases, offering a new approach that had previously been elusive for drugmakers.

## Clinical Trial Results

In a study involving 500 patients with metastatic pancreatic cancer, those treated with daraxonrasib lived a median of 13.2 months, compared to 6.7 months for those on chemotherapy. The drug also showed fewer severe side effects, such as skin rash and digestive issues.

## Impact and Future Prospects

While not a cure, daraxonrasib is considered the best option currently available for patients with this aggressive cancer. The drug's approval came more than six months ahead of schedule, reflecting its potential impact. Researchers hope this breakthrough will lead to more treatments for other cancers, as the drug's technology is being explored for use in lung cancer and other types.

Read the full story at the source

What you need to know to get Emirates ID?

Leave your details and get a guide as a gift to avoid mistakes

Article contents

LinkedIn X Facebook WhatsApp Telegram